Last reviewed · How we verify

Sevoflurane and Remifentanil

University General Hospital of Patras · FDA-approved active Small molecule

Sevoflurane is a volatile anesthetic that depresses the central nervous system, while remifentanil is a potent synthetic opioid that provides analgesia and enhances anesthesia.

Sevoflurane is a volatile anesthetic that depresses the central nervous system, while remifentanil is a potent synthetic opioid that provides analgesia and enhances anesthesia. Used for General anesthesia for surgical procedures, Induction and maintenance of anesthesia in adult and pediatric patients.

At a glance

Generic nameSevoflurane and Remifentanil
SponsorUniversity General Hospital of Patras
Drug classGeneral anesthetic (sevoflurane) and synthetic opioid analgesic (remifentanil)
TargetGABA receptors (sevoflurane); mu-opioid receptor (remifentanil)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Sevoflurane acts as a general anesthetic by enhancing inhibitory GABAergic neurotransmission and inhibiting excitatory glutamatergic signaling in the central nervous system, producing unconsciousness and amnesia. Remifentanil is a mu-opioid receptor agonist that provides rapid-onset analgesia and sedation through activation of opioid receptors in the brain and spinal cord. Together, they are commonly used as a balanced anesthetic combination for induction and maintenance of general anesthesia during surgery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: